



Zeal & Innovation in Medicine

ZIM LABORATORIES LIMITED

The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. By accessing this presentation, you are agreeing to be bound by the trading restrictions.

The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its affiliates, advisors or representatives are under an obligation to update, revise or affirm.

Certain statements contained in this presentation may be statements of the Company’s beliefs, plans and expectations about the future and other forward-looking statements. The forward-looking statements are based on management’s current expectations or beliefs as well as a number of assumptions about the Company’s operations and factors beyond the Company’s control or third-party sources and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. There is no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward looking statements, which speak only as of the date of this presentation.


The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. You acknowledge and agree that the Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed.

ZIM : A Brief Introduction


ZIM is a research driven pharmaceutical company that leverages on a range of technology based novel drug delivery solutions and non – infringing proprietary manufacturing processes to develop, manufacture and supply a wide range of innovative and differentiated generic pharmaceutical products

- ➊ Strong R&D expertise in complex generics and NDDS (Novel Drug Delivery Solution)
- ➋ Robust technology platforms capable to manufacture wide range of therapy- agnostic products
- ➌ Consistent and high quality supply of complex drugs
- ➍ Focused on improving patient convenience and adherence of drug treatment
- ➎ EU-GMP approved manufacturing facility

Technology Platforms



Liquid in Pellets



Stability Enhancement



Transmucosal Films Casting



Oral Films Casting



Taste Masking



Solvent Less Processing




Solubility Bioavailability Enhancement



Bi/Multi Layer Film Casting



Active Nano Particulate Granulation



Multi Layered Pellets

Strong R&D Capabilities

Patents Granted - 9

Dosage Form	Modified Drug Release	Solubility & Stability Enhancement	Dosage Transformation	Total
Pellets/Capsules	24	-	2	26
ODS	2	12	14	28
Tablets	4	-	-	4
Patent Filings	30	12	16	58

Patents under examination - 45

Product Registrations -595

Dosage Form	Registered	Applied	Pipeline	Total
Capsules/Tablets	396	210	30	636
Suspensions	23	31	-	54
ODS	136	107	4	247
Nutraceuticals	40	48	6	94

Registrations in Pipeline - 436

State of the art Manufacturing units



ORAL DOSAGE (GENERAL) (EU GMP)

Manufacturing Capabilities	Tablets, Capsules, DC Granules, Pellets and Dry Syrup
Accreditations	EU-GMP, ISO-9001

ORAL THIN FILM (EU GMP)

Manufacturing Capabilities	ORAL THIN FILM
Accreditations	EU-GMP, ISO-9001, NSF-ANSI 455-2



Oral Solid Dosages

Azithromycin Europe Marketing Authorisations

— ZIM received marketing authorisations:

Germany - Azithromycin ZIM Laboratories 500 mg Filmtabletten

Portugal – Comprimidos revestidos por película de azitromicina
ZIM 500 mg

Poland - Azithromycin ZIM

Products with CTD dossier

1. Azithromycin Tablets 250mg/500mg
2. Azithromycin Oral Suspension 200mg/5ml
3. Acitretin Capsules 10mg/25mg
4. Dabigatran Etexilate capsules
75mg/110mg/150mg
5. Dimethyl Fumarate DR capsules 120/240 mg
6. Dutasteride and Tamsulosin HCL capsules
0.5mg/0.4 mg
7. Mirabegron PR Tablets 25 mg/50 mg
8. Pancreatin capsules 10000 IU/ 25000 IU
9. Tofacitinib Citrate PR tablets 11mg
10. Tofacitinib Citrate tablets 5mg/10mg

Oral Thin Films (OTF):

Thinoral[®], Mucostrip[®], Printoral[®], Spinoral[®], Sublingual, Bi-layer

- ZIM's R&D team has developed Oral Thin Films (OTF) which are manufactured using the company's in house Patented Thinoral[®] technology. ZIM manufactures pharmaceuticals and nutraceuticals on Oro dispersible, Sublingual and Buccal thin film technologies.
- Recently, ZIM received MAs for 2 of its ODS products: Rizatriptan Benzoate in Portugal and Sildenafil Citrate in Spain
- We have 7 patents granted and 14 under examination in OTF

3 OTF products registered in EU

12 OTF Pharmaceutical Products Developed

Products with CTD Dossier



1. Rizatriptan Benzoate ODS
2. Sildenafil Citrate ODS
3. Ondansetron ODS
4. Tadalafil ODS
5. Vitamin D3 ODS
6. Melatonin ODS



- ZIM Labs' OTF plant is now NSF–ANSI 455-2 accredited for Dietary Supplements
- ZIM has developed a product basket of Nutraceuticals which complement our pharmaceutical products thus providing a holistic approach to patient health
- ZIM is working with differentiated generic active ingredients which are sourced naturally and chemically to create higher efficacy products and product differentiation

Products For Developed Markets

1. Nootropic Extended Release
2. Blood Sugar control pellets in capsules
3. Hangover Support
4. Liver Protectant
5. Anti Aging supplement with Liposomal formulations
6. PMS support for women
7. Caffeine + L-Theanine ODS
8. Liposomal Sleep Aid Capsules
9. Anti – Nausea with Ginger ODS

Partnership model



- Strategic R&D Partner to Global Companies
- Product Development, Manufacturing & Supply of PFI & Finished dosages
- Co-Development of New Products
- Out-Licensing of dossiers and Finished dosages supply
- Technology Transfer of Manufacturing processes
- Manufacturing of Complex Generics



Zeal & Innovation in Medicine

THANK YOU